Aimmune Therapeutics, Inc. (AIMT)
AIMT Price and Sentiment
AIMT Latest news
Aimmune Therapeutics to Present New Data at ACAAI on the Real-World Burden of Peanut Allergy and Early Physician Experience with PALFORZIA® in Clinical Practice in the U.S.2021-11-05 08:30
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc., a Nestlé Health Science company developing and commercializing pharmaceutical therapies to prevent, manage, and treat food and metabolic-related diseases, today announced it will present new data on the burden of peanut allergy (PA) on patients' and caregivers' Quality of Life. In addition, the company will share results from physician surveys on real-world experiences with PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp]
Aimmune to Present New Two-Year Treatment Satisfaction Data From Patients With Peanut Allergy at EAACI Hybrid Annual Congress 20212021-07-09 18:15
LONDON--(BUSINESS WIRE)--Aimmune Therapeutics UK Ltd., a Nestlé Health Science company developing and commercialising pharmaceutical therapies to prevent, manage, and treat food and metabolic related diseases, today announced it will present new treatment satisfaction data for its oral immunotherapy drug, PALFORZIA, at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2021 in Poland. The company will share updated treatment satisfaction data evaluated in its Phase
Investors don't need a crystal ball to see how major trends in sectors such as e-commerce and biotech are supporting the best stocks in 2020. The post 10 Best Stocks for 2020: Megatrends Support This Year's Biggest Winners appeared first on InvestorPlace.
Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Aimmune Therapeutics, Inc. In The Northern District Of California2020-10-15 19:28
NEW YORK, Oct. 15, 2020 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the Northern District of California, Case No. 4:20-cv-06733-YGR, on behalf of common shareholders of Aimmune...
Vevey, October 14, 2020
Aimmune Therapeutics Inc shareholders have backed Nestle's $2 billion offer to gain full ownership of the first U.S.-approved peanut allergy treatment, which has struggled with a slow launch due to the COVID-19 pandemic.
Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
Nestle picked my Best Stocks pick up for a steal, but I believe the decade of biotechnology is just now getting started. The post Best Stocks for 2020: Aimmune Therapeutics Gets Picked Up for a Steal appeared first on InvestorPlace.
AIMT's stock fell precipitously amid the COVID-19 pandemic, despite receiving FDA approval for its Palforzia treatment (the first FDA approved treatment for peanut allergies).
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics, Inc. - AIMT2020-09-18 20:00
NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Aimmune Therapeutics, Inc. ("Aimmune" or the "Company") (AIMT)...